Current Edition

Regulatory Response to Accelerate COVID-19 Drug Development

The FDA has created a special emergency programme for therapeutics known as the Coronavirus Treatment Acceleration Program (CTAP). This programme attempts to utilise all available methods to shepherd new treatments rapidly along the drug development pathway in an effort to reach patients as quickly as possible. Henry J. Riordan and Aman Khera at Worldwide Clinical Trials take a look at how the world has responded against COVID-19 in this regulatory report.